Printer Friendly

BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC

 BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
 PRINCETON, N.J., Jan. 3 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced that Cefzil(TM) (cefprozil) has been approved for marketing in the United States.
 Cefzil is a new oral cephalosporin antibiotic with a broad spectrum of activity.
 Cefzil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions of upper and lower respiratory tract infections and skin and skin structure infections.
 The company said it expects Cefzil to effectively compete with leading oral cephalosporins and broad-spectrum antimicrobial agents. Taken once or twice daily, Cefzil may enhance patient compliance. Cefzil will be available for physician prescribing in February 1992.
 Cefzil will compete in the United States oral antibiotic market, a large, growing market with annual sales approaching $3 billion. Nearly 200 million patients seek treatment each year for common outpatient respiratory and skin infections. More than 8,000 patients participated in the worldwide clinical testing of Cefzil.
 Bristol-Myers Squibb is a diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and over- the-counter medicines.
 /delval/
 -0- 1/3/92 R
 /CONTACT: Robert F. Laverty, 609-25Bristol-Myers Squibb/
 (BMY) CO: Bristol-Myers Squibb Company ST: Pennsylvania IN: MTC SU: PDT


LJ-JS -- PH010 -- 6479 01/03/92 11:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 3, 1992
Words:243
Previous Article:PROFESSIONAL BANCORP RESTRUCTURES PORTFOLIO
Next Article:JOHNSTONE SUCCEEDS LAFRANKIE AS PRESIDENT OF AMERICAN WATER
Topics:


Related Articles
BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL, A NEW CHOLESTEROL-LOWERING THERAPY
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC (Product Announcement)
Bristol-Myers Squibb Acquires Novel Fluoroquinolone From Kyorin
ZERIT - an Important New Option for Treating HIV-Infected Children - Now Available from Bristol-Myers Squibb Co.
Zerit(R) - An Important New Option For Treating HIV-Infected Children - Now Available
Bristol-Myers Squibb Company Announces FDA Marketing Clearance of OTC VAGISTAT-1; First One-Dose OTC Treatment for Vaginal Yeast Infections
Bristol-Myers Squibb Announces an Exclusive License Agreement With Dura Pharmaceuticals.
Bristol-Myers Squibb Files for Approval of New Antibiotic; Seeking Marketing Approval for TEQUIN(TM) to Treat Respiratory and Other Infections.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters